| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
69,174,000 |
| Market
Cap: |
628.10(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.64 - $17.21 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 9.2 |
| Insider 3/6 Months : 9.8 |
|
| Guru Rank Number : 574 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Avid Bioservices is a contract development and manufacturing organization that provides a range of services from process development to Current Good Manufacturing Practices (CGMP) clinical and commercial manufacturing, focused on biopharmaceutical drug substances derived from mammalian cell culture. Co. produces monoclonal antibodies and recombinant proteins, and its services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. Co. also provides process development services, including upstream and downstream development, analytical method development, testing and characterization.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
61,803 |
81,803 |
81,803 |
| Total Buy Value |
$0 |
$336,770 |
$527,466 |
$527,466 |
| Total People Bought |
0 |
1 |
2 |
2 |
| Total Buy Transactions |
0 |
2 |
3 |
3 |
| Total Shares Sold |
18,578 |
24,837 |
136,703 |
332,920 |
| Total Sell Value |
$137,460 |
$176,242 |
$1,628,455 |
$5,111,613 |
| Total People Sold |
5 |
5 |
6 |
8 |
| Total Sell Transactions |
6 |
12 |
38 |
69 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Walsh Patrick D |
Director |
– • – |
2020-03-23 |
4 |
B |
$3.22 |
$96,600 |
I/I |
30,000 |
30,000 |
2.1 |
102% |
|
| Hart Daniel Ryan |
Chief Financial Officer |
• – – |
2020-03-16 |
4 |
B |
$3.75 |
$28,255 |
D/D |
7,500 |
12,482 |
2.74 |
84% |
|
| Bamforth Mark R |
Director |
– • – |
2020-03-13 |
4 |
B |
$4.01 |
$104,260 |
I/I |
26,000 |
26,000 |
2.1 |
76% |
|
| Carleone Joseph |
Director |
– • – |
2020-03-13 |
4 |
B |
$4.01 |
$50,125 |
D/D |
12,500 |
66,945 |
2.39 |
76% |
|
| Hancock Richard B |
Interim President & CEO |
• • – |
2020-03-13 |
4 |
B |
$3.99 |
$49,875 |
D/D |
12,500 |
22,500 |
2.81 |
76% |
|
| Hart Daniel Ryan |
Chief Financial Officer |
• – – |
2019-10-31 |
4 |
A |
$3.94 |
$10,621 |
D/D |
2,693 |
4,982 |
|
- |
|
| Carleone Joseph |
Director |
– • – |
2019-09-10 |
4 |
B |
$5.00 |
$50,500 |
D/D |
10,000 |
54,445 |
2.39 |
- |
|
| Hancock Richard B |
Interim President & CEO |
• • – |
2019-09-10 |
4 |
B |
$5.08 |
$50,910 |
D/D |
10,000 |
10,000 |
2.81 |
- |
|
| Hart Daniel Ryan |
Chief Financial Officer |
• – – |
2019-04-30 |
4 |
A |
$4.07 |
$9,320 |
D/D |
2,289 |
2,289 |
|
- |
|
| Lias Roger J. |
President & CEO |
• • – |
2019-04-30 |
4 |
A |
$4.07 |
$9,320 |
D/D |
2,289 |
2,289 |
|
- |
|
| Mccomb Joel |
Director |
– • – |
2018-09-20 |
4 |
S |
$6.57 |
$159,500 |
D/D |
(24,267) |
0 |
|
- |
|
| Mccomb Joel |
Director |
– • – |
2018-09-19 |
4 |
S |
$6.48 |
$166,786 |
D/D |
(25,733) |
24,267 |
|
- |
|
| Mccomb Joel |
Director |
– • – |
2018-02-15 |
4 |
B |
$2.25 |
$112,500 |
D/D |
50,000 |
50,000 |
2.39 |
- |
|
| Bamforth Mark R |
Director |
– • – |
2018-02-15 |
4 |
B |
$2.25 |
$112,500 |
D/D |
50,000 |
100,000 |
2.39 |
- |
|
| Carleone Joseph |
Director |
– • – |
2018-02-15 |
4 |
B |
$2.25 |
$100,001 |
D/D |
44,445 |
44,445 |
2.39 |
- |
|
| King Steven W |
President & CEO |
• • – |
2017-10-31 |
4 |
A |
$3.87 |
$5,407 |
D/D |
1,398 |
34,646 |
|
- |
|
| Shan Joseph |
VP, Clinical and Reg Affairs |
• – – |
2017-10-31 |
4 |
A |
$3.87 |
$10,624 |
D/D |
2,747 |
16,187 |
|
- |
|
| Bamforth Mark R |
Director |
– • – |
2017-10-27 |
4 |
B |
$4.48 |
$225,091 |
D/D |
50,000 |
50,000 |
2.39 |
- |
|
| King Steven W |
President & CEO |
• • – |
2017-04-28 |
4 |
A |
$0.27 |
$5,408 |
D/D |
19,941 |
232,730 |
|
- |
|
| Lytle Paul J |
Chief Financial Officer |
• – – |
2017-04-28 |
4 |
A |
$0.27 |
$10,140 |
D/D |
37,389 |
184,038 |
|
- |
|
| Shan Joseph |
VP, Clinical and Reg Affairs |
• – – |
2017-04-28 |
4 |
A |
$0.27 |
$10,625 |
D/D |
39,177 |
94,079 |
|
- |
|
| Shan Joseph |
VP, Clinical and Reg Affairs |
• – – |
2016-10-31 |
4 |
A |
$0.29 |
$9,675 |
D/D |
33,783 |
54,902 |
|
- |
|
| Lytle Paul J |
Chief Financial Officer |
• – – |
2016-10-31 |
4 |
A |
$0.29 |
$9,675 |
D/D |
33,783 |
146,649 |
|
- |
|
| King Steven W |
President & CEO |
• • – |
2016-10-31 |
4 |
A |
$0.29 |
$5,392 |
D/D |
18,826 |
212,789 |
|
- |
|
| Fussey Shelley Pm |
V.P., Intellectual Property |
• – – |
2016-10-31 |
4 |
A |
$0.29 |
$7,284 |
D/D |
25,433 |
135,908 |
|
- |
|
288 Records found
|
|
Page 11 of 12 |
|
|
0.20 (2.16%) 
